News Sandoz launches first biosimilar Tysabri in US Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.
News FDA plan will cut testing requirements for biosimilars The FDA has proposed a radical change to the regulatory requirements for bringing biosimilar medicines to market as a way to cut US drug prices.
R&D How Europe can harness the full potential of biosimilars Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.
News IPO plan evaporates as private equity firm buys Stada Stada has confirmed it isn't going ahead with an IPO, as its two private equity owners have just agreed to sell a majority stake to a third.
News Stada revives talk of an IPO – if conditions improve Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.
Patients Biosimilars: Unlocking access, closing the cost divide Every day, countless Americans are forced to choose between meeting basic needs such as food, housing, or transportation and paying for their medications.
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
